The generation of hematopoietic stem cells (HSCs) from induced pluripotent stem cells
(iPSCs) is an active and promising area of research; however, generating engraftable HSCs …

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide
remarkable cellular platforms to better understand human hematopoiesis and to develop …

The ability to manufacture human hematopoietic stem cells (HSCs) in the laboratory holds
enormous promise for cellular therapy of human blood diseases. Several differentiation …

Over the past decade, enormous progress has been made in the field of induced pluripotent
stem cells (iPSCs). Patients' somatic cells such as skin fibroblasts or blood cells can be used …

The discovery of human embryonic stem cells (hESCs) raised promises for a universal
resource for cell based therapies in regenerative medicine. Recently, fast-paced progress …

Previous attempts to either generate or expand hematopoietic stem cells (HSCs) in vitro
have involved either ex vivo expansion of pre-existing patient or donor HSCs or de novo …

Pluripotent stem cells (PSC s) such as embryonic stem cells or induced pluripotent stem
cells represent a promising cell type to gain novel insights into human biology …

Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have opened up a
world of possibilities for regenerative medicine and novel cell-based therapeutics. Now, over …

Significant advances in cellular reprogramming technologies and hematopoietic
differentiation from human pluripotent stem cells (hPSCs) have already enabled the routine …

Inherited blood disorders comprise a large spectrum of diseases due to germline mutations
in genes with key function in the hematopoietic system; they include immunodeficiencies …